Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

被引:16
作者
Haltia, Ulla-Maija [1 ,2 ,3 ]
Hallamaa, Marianne [4 ,5 ]
Tapper, Johanna [1 ,2 ]
Hynninen, Johanna [4 ,5 ]
Alfthan, Henrik [6 ,7 ]
Kalra, Bhanu [8 ]
Ritvos, Olli [9 ]
Heikinheimo, Markku [2 ,3 ,10 ]
Unkila-Kallio, Leila [1 ,2 ]
Perheentupa, Antti [4 ,5 ,11 ]
Farkkila, Anniina [1 ,2 ,3 ]
机构
[1] Univ Helsinki, Obstet & Gynecol, POB 20, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Helsinki Univ Hosp, POB 20, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Childrens Hosp, POB 20, FIN-00014 Helsinki, Finland
[4] Univ Turku, Dept Obstet & Gynecol, FIN-20520 Turku, Finland
[5] Turku Univ Hosp, FIN-20520 Turku, Finland
[6] Univ Helsinki, Clin Chem, Helsinki, Finland
[7] HUSLAB, Helsinki, Finland
[8] AnshLabs, Webster, TX USA
[9] Univ Helsinki, Fac Med, Physiol, Helsinki, Finland
[10] Washington Univ, Sch Med, Dept Pediat, St Louis Childrens Hosp, St Louis, MO 63110 USA
[11] Univ Turku, Dept Physiol, Inst Biomed, Turku 20014, Finland
基金
芬兰科学院;
关键词
AMH; CA125; Granulosa cell tumor; HE4; Inhibin B; Ovarian cancer; MALIGNANCY ALGORITHM ROMA; SERUM HE-4 CONCENTRATION; CA125; CANCER; RISK; INDEX; CARCINOMAS; SURVIVAL; TOOLS;
D O I
10.1016/j.ygyno.2016.11.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Evaluation of circulating tumor markers in ovarian cancer is crucial for optimal patient care. The goal of this study was to verify the most accurate circulating tumor markers for the diagnosis and follow-up of adult-type granulosa cell tumors (AGCT5). Methods. The levels of circulating human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125), together with AGCT markers inhibin B and anti-Mtillerian hormone (AMH), were measured in 135 samples from AGCT patients, 37 epithelial ovarian carcinoma (EOC) patients, and 40 endometrioma (ENDO) patients. The levels were plotted with receiver operating characteristic (ROC) graphs, and the area under the curves (AUC) of the different markers were calculated and compared. Results. HE4 levels were significantly lower in AGCT5 than in EOCs (p < 0.0001). CA125 levels were above 35 IU/1 in 25% of AGCT patients and 47.5% of ENDO patients, whereas inhibin B and AMH levels were elevated only in patients with AGCT5. In the AUC comparison analyses, inhibin B alone was sufficient to differentiate AGCT from EOC. In differentiating AGCT from ENDO, inhibin B and AMH performed similarly, and the combination of inhibin B and AMH increased the accuracy compared to either marker alone (sensitivity, 100%; specificity, 93%). Among AGCT patients, inhibin B was the best marker for detecting the presence of AGCT. Conclusions. HE4 and CA125 levels were low in AGCTs, and inhibin B was the most accurate circulating biomarker in distinguishing AGCTs from EOCs and from ENDOs. Inhibin B was also the best single marker for AGCT follow-up. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 40 条
[1]  
Anniina M.M.K. Farkkila, 2016, J MOL DIAGN
[2]   Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases [J].
Ayhan, Ali ;
Salman, Mehmet Coskun ;
Velipasaoglu, Melih ;
Sakinci, Mehmet ;
Yuce, Kunter .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2009, 30 (03) :158-163
[3]   Human epididymis protein 4 reference limits and natural variation in a Nordic reference population [J].
Bolstad, Nils ;
Oijordsbakken, Miriam ;
Nustad, Kjell ;
Bjerner, Johan .
TUMOR BIOLOGY, 2012, 33 (01) :141-148
[4]   Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors [J].
Bryk, Saara ;
Farkkila, Anniina ;
Butzow, Ralf ;
Leminen, Arto ;
Tapper, Johanna ;
Heikinheimo, Markku ;
Unkila-Kallio, Leila ;
Riska, Annika .
GYNECOLOGIC ONCOLOGY, 2016, 143 (03) :571-577
[5]   Clinical Characteristics and Survival of Patients With an Adult-Type Ovarian Granulosa Cell Tumor A 56-Year Single-Center Experience [J].
Bryk, Saara ;
Farkkila, Anniina ;
Butzow, Ralf ;
Leminen, Arto ;
Heikinheimo, Markku ;
Anttonen, Mikko ;
Riska, Annika ;
Unkila-Kallio, Leila .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (01) :33-41
[6]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[7]   Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients [J].
Earle, CC ;
Schrag, D ;
Neville, BA ;
Yabroff, KR ;
Topor, M ;
Fahey, A ;
Trimble, EL ;
Bodurka, DC ;
Bristow, RE ;
Carney, M ;
Warren, JL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (03) :172-180
[8]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[9]   Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma [J].
Engelen, MJA ;
Kos, HE ;
Willemse, PHB ;
Aalders, JG ;
de Vries, EGE ;
Schaapveld, M ;
Otter, R ;
van der Zee, AGJ .
CANCER, 2006, 106 (03) :589-598
[10]   The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumorsA comparative study with inhibin B [J].
Farkkila, Anniina ;
Koskela, Sanna ;
Bryk, Saara ;
Alfthan, Henrik ;
Butzow, Ralf ;
Leminen, Arto ;
Puistola, Ulla ;
Tapanainen, Juha S. ;
Heikinheimo, Markku ;
Anttonen, Mikko ;
Unkila-Kallio, Leila .
INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (07) :1661-1671